Advancing Cancer Immunotherapy Toward Clinical Trials
CIEF supports the development of a published immunotherapy approach that has shown promising preclinical results and now requires clinical testing.
The mission of the Cancer Immunotherapy Endowment Fund is direct and clear: Our goal is to bring MBTA cancer immunotherapy to clinical trials and ultimately into the hands of physicians.
Scientific Foundation
Peer-reviewed publications describe the biological mechanisms and preclinical results of the immunotherapy approach supported by CIEF.
Path to Clinical Trials
Promising laboratory findings must undergo strict development steps before they can be tested in patients. CIEF supports the transition from research to clinical evaluation.
Support the Mission
Advancing scientific research toward clinical testing requires significant resources. Your support helps move promising research closer to clinical trials.
Your support helps advance a published, evidence-based immunotherapy approach toward clinical trials.
Clinical trials are the essential step that determines whether promising laboratory findings can translate into real patient benefit.
⚠️ Important notice:
MBTA therapy cannot be used in clinical practice outside properly approved clinical trials. Clinical testing is required to evaluate its safety and potential effectiveness in patients.